MetaVia doses first patient in higher-dose Phase 1 study of DA-1726 for obesity

MetaVia Inc.

Part 3 of Phase 1 evaluates one-step (16→48 mg) and two-step (16→32→64 mg) titration over 16 weeks in 40 obese adults.
Previously reported ~9% weight loss at 48 mg dose with favorable tolerability; glycemic and liver benefit signals.
Data from Part 3 expected in Q4 2026; primary endpoints are safety and tolerability.
DA-1726 is a dual GLP-1/glucagon (OXM) analog; company aims for differentiated efficacy and simpler titration.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.